Table 4 Results of Fung et al., 2003, meta-analysis.
No of trials | regimens | No of patients | Average median an survival(months) | Hazard ratio | p-value |
|---|---|---|---|---|---|
9 | Best supportive care vs. 5-FU based combinations | 434 262 | 3.87 6.38 | 0.53 | <0.0001 |
7 | 5-FU/other agent alone vs. 5-FU based combination | 428 414 | 5.23 4.98 | 0.88 | 0.1 |
3 | 5-FU based combination vs. 5-FU based combination | 121 121 | 3.75 4.38 | 0.85 | 0.25 |
1 | 5-FU vs. Gemcitabine | 63 63 | 4.41 5.65 | 0.56 | <0.005 |
2 | Miscellaneous new agent vs. Gemcitabine | 241 242 | 3.70 6.08 | 0.61 | <0.0001 |
7 | Gemcitabine vs. Gemcitabine based combination | 758 745 | 6.62 6.98 | 0.92 | 0.15 |